Maria I Menendez, Bianca Hettlich, Lai Wei, Michael V Knopp
{"title":"Feasibility of Na<sup>18</sup>F PET/CT and MRI for Noninvasive In Vivo Quantification of Knee Pathophysiological Bone Metabolism in a Canine Model of Post-traumatic Osteoarthritis.","authors":"Maria I Menendez, Bianca Hettlich, Lai Wei, Michael V Knopp","doi":"10.1177/1536012117714575","DOIUrl":"https://doi.org/10.1177/1536012117714575","url":null,"abstract":"<p><strong>Purpose: </strong>To assess and quantify by molecular imaging knee osseous metabolic changes serially in an in vivo canine model of posttraumatic osteoarthritis (PTOA) of the knee utilizing sodium fluoride (Na<sup>18</sup>F) positron emission tomography (PET)/computed tomography (CT) coregistered with magnetic resonance imaging (MRI).</p><p><strong>Materials and methods: </strong>Sodium fluoride PET imaging of 5 canines was performed prior to anterior cruciate ligament transection (ACLT) and 2 times post-ACLT (3 and 12 weeks). The PET/CT was coregistered with MRI, enabling serial anatomically guided visual and quantitative three-dimensional (3D) region of interest (ROI) assessment by maximum standardized uptake value.</p><p><strong>Results: </strong>Prior to ACLT, every 3D ROI assessed in both knees showed no Na<sup>18</sup>F uptake above background. The uptake of Na<sup>18</sup>F in the bone of the ACLT knees increased exponentially, presenting significantly higher uptake at 12 weeks in every region compared to the ACLT knees at baseline. Furthermore, the uninjured contralateral limb and the ipsilateral distal bones and joints presented Na<sup>18</sup>F uptake at 3 and 12 weeks post-ACLT.</p><p><strong>Conclusion: </strong>This study demonstrated that Na<sup>18</sup>F PET/CT coregistered with MRI is a feasible molecular imaging biomarker to assess knee osseous metabolic changes serially in an in vivo canine model of knee PTOA. Moreover, it brings a novel musculoskeletal preclinical imaging methodology that can provide unique insights into PTOA pathophysiology.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117714575"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117714575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35188575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Samit Chatterjee, Wojciech G Lesniak, Sridhar Nimmagadda
{"title":"Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy.","authors":"Samit Chatterjee, Wojciech G Lesniak, Sridhar Nimmagadda","doi":"10.1177/1536012117718459","DOIUrl":"https://doi.org/10.1177/1536012117718459","url":null,"abstract":"<p><p>Immunotherapy holds great promise in cancer treatment. The challenges in advancing immunotherapies lie in patient stratification and monitoring therapy. Noninvasive detection of immune checkpoint ligand PD-L1 can serve as an important biomarker for guidance and monitoring of immunotherapy. Here in, we provide an overview of our efforts to develop clinically translatable PD-L1-specific imaging agents for quantitative and real-time assessment of PD-L1 expression in tumor microenvironment.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117718459"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117718459","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35167523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Spencer C Behr, Brett J Mollard, Jaewon Yang, Robert R Flavell, Randall A Hawkins, Youngho Seo
{"title":"Effect of Time-of-Flight and Regularized Reconstructions on Quantitative Measurements and Qualitative Assessments in Newly Diagnosed Prostate Cancer With <sup>18</sup>F-Fluorocholine Dual Time Point PET/MRI.","authors":"Spencer C Behr, Brett J Mollard, Jaewon Yang, Robert R Flavell, Randall A Hawkins, Youngho Seo","doi":"10.1177/1536012117736703","DOIUrl":"10.1177/1536012117736703","url":null,"abstract":"<p><p>Recent technical advances in positron emission tomography/magnetic resonance imaging (PET/MRI) technology allow much improved time-of-flight (TOF) and regularized iterative PET reconstruction regularized iterative reconstruction (RIR) algorithms. We evaluated the effect of TOF and RIR on standardized uptake values (maximum and peak SUV [SUV<sub>max</sub> and SUV<sub>peak</sub>]) and their metabolic tumor volume dependencies and visual image quality for <sup>18</sup>F-fluorocholine PET/MRI in patients with newly diagnosed prostate cancer. Fourteen patients were administered with 3 MBq/kg of <sup>18</sup>F-fluorocholine and scanned dynamically for 30 minutes. Positron emission tomography images were divided to early and late time points (1-6 minutes summed and 7-30 minutes summed). The values of the different SUVs were documented for dominant PET-avid lesions, and metabolic tumor volume was estimated using a 50% isocontour and SUV threshold of 2.5. Image quality was assessed via visual acuity scoring (VAS). We found that incorporation of TOF or RIR increased lesion SUVs. The lesion to background ratio was not improved by TOF reconstruction, while RIR improved the lesion to background ratio significantly ( P < .05). The values of the different VAS were all significantly higher ( P < .05) for RIR images over TOF, RIR over non-TOF, and TOF over non-TOF. In conclusion, our data indicate that TOF or RIR should be incorporated into current protocols when available.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117736703"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8e/a0/10.1177_1536012117736703.PMC5703093.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35638614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jarrod D Predina, Andrew Newton, Greg Kennedy, M Kenneth Lee, Sunil Singhal
{"title":"Near-Infrared Intraoperative Imaging Can Successfully Identify Malignant Pleural Mesothelioma After Neoadjuvant Chemotherapy.","authors":"Jarrod D Predina, Andrew Newton, Greg Kennedy, M Kenneth Lee, Sunil Singhal","doi":"10.1177/1536012117723785","DOIUrl":"https://doi.org/10.1177/1536012117723785","url":null,"abstract":"<p><p>Malignant pleural mesothelioma is a deadly disease. Complete surgical resection provides patients with the best opportunity for long-term survival. Unfortunately, identification of disease during resection can be challenging. In this report, we describe successful intraoperative utilization of the near-infrared imaging agent, indocyanine green, to help the surgeon identify malignant disease in a patient with malignant pleural mesothelioma who had previously received neoadjuvant chemotherapy. This technology may ultimately enhance the thoracic surgeon's ability to identify small disease deposits at the time of resection.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117723785"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117723785","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35313102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Benjamin L Franc, Sam Goth, John MacKenzie, Xiaojuan Li, Joseph Blecha, Tina Lam, Salma Jivan, Randall A Hawkins, Henry VanBrocklin
{"title":"In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis.","authors":"Benjamin L Franc, Sam Goth, John MacKenzie, Xiaojuan Li, Joseph Blecha, Tina Lam, Salma Jivan, Randall A Hawkins, Henry VanBrocklin","doi":"10.1177/1536012117712638","DOIUrl":"https://doi.org/10.1177/1536012117712638","url":null,"abstract":"<p><strong>Background: </strong>Evolving immune-mediated therapeutic strategies for rheumatoid arthritis (RA) may benefit from an improved understanding of the complex role that T-cell activation plays in RA. This study assessed the potential of fluorine-18-labeled 9-β-d-arabinofuranosylguanine ([<sup>18</sup>F]F-AraG) positron emission tomography (PET) imaging to report immune activation in vivo in an adjuvant-induced arthritis (AIA) small animal model.</p><p><strong>Methods: </strong>Using positron emission tomography-computed tomography imaging, uptake of [<sup>18</sup>F]F-AraG in the paws of mice affected by arthritis at 6 (acute) and 20 (chronic) days following AIA induction in a single paw was assessed and compared to uptake in contralateral control paws. Fractions of T cells and B cells demonstrating markers of activation at the 2 time points were determined by flow cytometry.</p><p><strong>Results: </strong>Differential uptake of [<sup>18</sup>F]F-AraG was demonstrated on imaging of the affected joint when compared to control at both acute and chronic time points with corresponding changes in markers of T-cell activation observed on flow cytometry.</p><p><strong>Conclusion: </strong>[<sup>18</sup>F]F-AraG may serve as an imaging biomarker of T-cell activation in inflammatory arthritis. Further development of this technique is warranted and could offer a tool to explore the temporal link between activated T cells and RA as well as to monitor immune-mediated therapies for RA in clinical trials.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117712638"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117712638","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35097717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Perspective of αvβ6-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions.","authors":"Katja Steiger, Anna-Melissa Schlitter, Wilko Weichert, Irene Esposito, Hans-Jürgen Wester, Johannes Notni","doi":"10.1177/1536012117709384","DOIUrl":"10.1177/1536012117709384","url":null,"abstract":"<p><p>ß<sub>6</sub>-integrin immunohistochemistry analysis of a large number of pancreatic ductal adenocarcinoma (PDAC, 383 primary tumors, 7 lymph node, and 8 distant metastases) and 34 pancreatic intraepithelial neoplasia (PanIN) specimens revealed a high prevalence of α<sub>v</sub>ß<sub>6</sub>-integrin expression in PDAC primaries (88%) and in almost all metastases, as well as in PanIN (57%). These findings underscore the high potential of a novel α<sub>v</sub>ß<sub>6</sub>-integrin targeting positron emission tomography (PET) radiopharmaceutical, Ga-68-Avebehexin, for early diagnosis of pancreatic cancer.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117709384"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117709384","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35099088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emre Demirci, Rafay Ahmed, Meltem Ocak, Joseph Latoche, April Radelet, Nicole DeBlasio, N Scott Mason, Carolyn J Anderson, James M Mountz
{"title":"Preclinical Evaluation of <sup>18</sup>F-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors.","authors":"Emre Demirci, Rafay Ahmed, Meltem Ocak, Joseph Latoche, April Radelet, Nicole DeBlasio, N Scott Mason, Carolyn J Anderson, James M Mountz","doi":"10.1177/1536012116685941","DOIUrl":"https://doi.org/10.1177/1536012116685941","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated 2-(5-fluoro-pentyl)-2-methyl-malonic acid (<sup>18</sup>F-ML-10) positron emission tomography (PET) imaging of apoptosis posttherapy to determine optimal timing for predicting chemotherapy response in a mouse head/neck xenograft cancer model.</p><p><strong>Procedures: </strong>BALB/c nude mice (4-8 weeks old) were implanted with UM-SCC-22B tumors. The treatment group received 2 doses of doxorubicin (10 mg/kg, days 0, 2). Small animal <sup>18</sup>F-ML-10 PET/computed tomography was performed before and on days 1, 3, and 7 postchemotherapy. Using regions of interest around tumors, <sup>18</sup>F-ML-10 uptake change was measured as %ID/g and uptake relative to liver. Terminal Uridine Nick-End Labeling (TUNEL) immunohistochemistry assay was performed using tumor samples of baseline and on days 1, 3, and 7 posttreatment.</p><p><strong>Results: </strong>Treated mice demonstrated increased <sup>18</sup>F-ML-10 uptake compared to baseline and controls, and 10 of 13 mice showed tumor volume decreases. All control mice showed tumor volume increases. Tumor-to-liver (T/L) ratios from the control group mice did not show significant change from baseline ( P > .05); however, T/L ratios of the treatment group showed significant <sup>18</sup>F-ML-10 uptake differences from baseline compared to days 3 and 7 posttreatment ( P < .05), but no significant difference at 1 day posttreatment.</p><p><strong>Conclusion: </strong>2-(5-Fluoro-pentyl)-2-methyl-malonic acid PET imaging has the potential for early assessment of treatment-induced apoptosis. Timing and image analysis strategies may require optimization, depending on the type of tumor and cancer treatment.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012116685941"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012116685941","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35125048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In Joon Lee, Ji Yong Park, Young-Il Kim, Yun-Sang Lee, Jae Min Jeong, Jaeil Kim, Euishin Edmund Kim, Keon Wook Kang, Dong Soo Lee, Seonji Jeong, Eun Jeong Kim, Young Il Kim, Jin Wook Chung
{"title":"Image-Based Analysis of Tumor Localization After Intra-Arterial Delivery of Technetium-99m-Labeled SPIO Using SPECT/CT and MRI.","authors":"In Joon Lee, Ji Yong Park, Young-Il Kim, Yun-Sang Lee, Jae Min Jeong, Jaeil Kim, Euishin Edmund Kim, Keon Wook Kang, Dong Soo Lee, Seonji Jeong, Eun Jeong Kim, Young Il Kim, Jin Wook Chung","doi":"10.1177/1536012116689001","DOIUrl":"https://doi.org/10.1177/1536012116689001","url":null,"abstract":"<p><p>The aim of this study is to evaluate the localization of <sup>99m</sup>Tc-labeled dextran-coated superparamagnetic iron oxide (SPIO) nanoparticles to the liver tumor using image-based analysis. We delivered <sup>99m</sup>Tc-SPIO intravenously or intra-arterially (IA) with/without Lipiodol to compare the tumor localization by gamma scintigraphy, single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI) in a rabbit liver tumor. The gamma and SPECT image-based analysis shows that the uptake ratio of the tumor to the normal liver parenchyma is highest after delivery of <sup>99m</sup>Tc-SPIO with Lipiodol IA and that well correlates with the trend of the signal decrease in the liver MRIs. Intra-arterial delivery of SPIO with Lipiodol might be a good drug delivery system targeting the hepatic tumors, as confirmed by image-based analysis.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012116689001"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012116689001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35125049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nana L Christensen, Steen Jakobsen, Anna C Schacht, Ole L Munk, Aage K O Alstrup, Lars P Tolbod, Hendrik J Harms, Søren Nielsen, Lars C Gormsen
{"title":"Whole-Body Biodistribution, Dosimetry, and Metabolite Correction of [<sup>11</sup>C]Palmitate: A PET Tracer for Imaging of Fatty Acid Metabolism.","authors":"Nana L Christensen, Steen Jakobsen, Anna C Schacht, Ole L Munk, Aage K O Alstrup, Lars P Tolbod, Hendrik J Harms, Søren Nielsen, Lars C Gormsen","doi":"10.1177/1536012117734485","DOIUrl":"https://doi.org/10.1177/1536012117734485","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the decades long use of [<sup>11</sup>C]palmitate positron emission tomography (PET)/computed tomography in basic metabolism studies, only personal communications regarding dosimetry and biodistribution data have been published.</p><p><strong>Methods: </strong>Dosimetry and biodistribution studies were performed in 2 pigs and 2 healthy volunteers by whole-body [<sup>11</sup>C]palmitate PET scans. Metabolite studies were performed in 40 participants (healthy and with type 2 diabetes) under basal and hyperinsulinemic conditions. Metabolites were estimated using 2 approaches and subsequently compared: Indirect [<sup>11</sup>C]CO<sub>2</sub> release and parent [<sup>11</sup>C]palmitate measured by a solid-phase extraction (SPE) method. Finally, myocardial fatty acid uptake was calculated in a patient cohort using input functions derived from individual metabolite correction compared with population-based metabolite correction.</p><p><strong>Results: </strong>In humans, mean effective dose was 3.23 (0.02) µSv/MBq, with the liver and myocardium receiving the highest absorbed doses. Metabolite correction using only [<sup>11</sup>C]CO<sub>2</sub> estimates underestimated the fraction of metabolites in studies lasting more than 20 minutes. Population-based metabolite correction showed excellent correlation with individual metabolite correction in the cardiac PET validation cohort.</p><p><strong>Conclusion: </strong>First, mean effective dose of [<sup>11</sup>C]palmitate is 3.23 (0.02) µSv/MBq in humans allowing multiple scans using ∼300 MBq [<sup>11</sup>C]palmitate, and secondly, population-based metabolite correction compares well with individual correction.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117734485"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117734485","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35491442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molecular Imaging and Radionuclide Therapy of Melanoma Targeting the Melanocortin 1 Receptor.","authors":"Chengcheng Zhang, Kuo-Shyan Lin, François Bénard","doi":"10.1177/1536012117737919","DOIUrl":"https://doi.org/10.1177/1536012117737919","url":null,"abstract":"<p><p>Melanoma is a deadly disease at late metastatic stage, and early diagnosis and accurate staging remain the key aspects for managing melanoma. The melanocortin 1 receptor (MC1 R) is overexpressed in primary and metastatic melanomas, and its endogenous ligand, the α-melanocyte-stimulating hormone (αMSH), has been extensively studied for the development of MC1 R-targeted molecular imaging and therapy of melanoma. Natural αMSH is not well suited for this purpose due to low stability in vivo. Unnatural amino acid substitutions substantially stabilized the peptide, while cyclization via lactam bridge and metal coordination further improved binding affinity and stability. In this study, we summarized the development and the in vitro and in vivo characteristics of the radiolabeled αMSH analogues, including <sup>99m</sup>Tc-, <sup>111</sup>In-, <sup>67</sup> Ga-, or <sup>125</sup>I-labeled αMSH analogues for imaging with single-photon emission computed tomography; <sup>68</sup>Ga-, <sup>64</sup>Cu-, or <sup>18</sup>F-labeled αMSH analogues for imaging with positron emission tomography; and <sup>188</sup>Re-, <sup>177</sup>Lu-, <sup>90</sup>Y-, or <sup>212</sup>Pb-labeled αMSH analogues for radionuclide therapy. These radiolabeled αMSH analogues showed promising results with high tumor uptake and rapid normal tissue activity clearance in the preclinical model of B16F1 and B16F10 mouse melanomas. These results highlight the potential of using radiolabeled αMSH analogues in clinical applications for molecular imaging and radionuclide therapy of melanoma.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":"16 ","pages":"1536012117737919"},"PeriodicalIF":2.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1536012117737919","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35647048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}